CO6241167A2 - Arn circular monocatenario y metodo para producirlo - Google Patents
Arn circular monocatenario y metodo para producirloInfo
- Publication number
- CO6241167A2 CO6241167A2 CO09140877A CO09140877A CO6241167A2 CO 6241167 A2 CO6241167 A2 CO 6241167A2 CO 09140877 A CO09140877 A CO 09140877A CO 09140877 A CO09140877 A CO 09140877A CO 6241167 A2 CO6241167 A2 CO 6241167A2
- Authority
- CO
- Colombia
- Prior art keywords
- strand
- nucleotide sequence
- antisense strand
- unpaired nucleotides
- circular rna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/532—Closed or circular
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
1.- Un ARN circular monocatenario que tiene un efecto de interferencia de ARN sostenido o de liberación lenta, caracterizado porque el ARN circular monocatenario comprende una secuencia de hebras sentido, una secuencia de hebras antisentido que es complementaria de la secuencia de hebras sentido, secuencias de dos bucles idénticas o diferentes entre la hebra sentido y la hebra antisentido, que conectan ambas hebras, donde la hebra sentido y la hebra antisentido se aparean para formar un tallo. 2.- El ARN circular monocatenario según la raivindicación 1, donde la expresión de un ARN diana es 0,40 menor 24 horas después de introducir el ARN circular monocatenario en células eucariotas, en comparación con las células de control, cuyo nivel de expresión del ARN diana se establece en 1. 3.- El ARN circular monocatenario según la reivindicación 1 ó 2, donde el 70% o más de éste se retiene después de permanecer 8 horas en el suero humano. 4.- Un método para producir el ARN circular rnonocatenario según cualquiera de las reivindicaciones 1 a 3, que comprende sintetizar una hebra sentido y una hebra antisentido, y ambas comprenden una secuencia de nucleótidos con nucleótidos no-apareados en el extremo 5' y en el extremo 3', y simultáneamente se liga el nucleótido en el extremo 5' de la secuencia de nucleótidos con nucleótidos no-apareados en la hebra sentido, con el nucleótido en el extremo 3' de la secuencia de nucleótidos con nucleótidos no-apareados en la hebra antisentido y viceversa, utilizando una ligasa, donde la secuencia de nucleótidos con nucleótidos no-apareados en el extremo 5' de la hebra sentido y la secuencia de nucleótidos con nucleótidos no-apareados en el extremo 3' de la hebra antisentido se enlazan entre sí para formar un bucle, la secuencia de nucleótidos con nucleótidos no-apareados en el extremo 3' de la hebra sentido y la secuencia de nucleótidos con nucleótidos no-apareados en el extremo 5' de la hebra antisentido se enlazan entre sí para formar un bucle, y la hebra sentido y la hebra antisentido se aparean para formar un tallo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007125045A JP5296328B2 (ja) | 2007-05-09 | 2007-05-09 | 1本鎖環状rnaおよびその製造方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6241167A2 true CO6241167A2 (es) | 2011-01-20 |
Family
ID=40002313
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO09140877A CO6241167A2 (es) | 2007-05-09 | 2009-12-09 | Arn circular monocatenario y metodo para producirlo |
Country Status (26)
Country | Link |
---|---|
US (3) | US20100137407A1 (es) |
EP (1) | EP2143792B1 (es) |
JP (1) | JP5296328B2 (es) |
KR (1) | KR101525633B1 (es) |
CN (1) | CN101679962A (es) |
AR (1) | AR072034A1 (es) |
AU (1) | AU2008250075B2 (es) |
BR (1) | BRPI0811440A2 (es) |
CA (1) | CA2685994A1 (es) |
CO (1) | CO6241167A2 (es) |
CY (1) | CY1115283T1 (es) |
DK (1) | DK2143792T3 (es) |
ES (1) | ES2446040T3 (es) |
HK (1) | HK1135140A1 (es) |
HR (1) | HRP20140170T1 (es) |
IL (1) | IL201975A (es) |
MX (1) | MX2009011101A (es) |
MY (1) | MY154495A (es) |
NZ (1) | NZ581251A (es) |
PL (1) | PL2143792T3 (es) |
PT (1) | PT2143792E (es) |
RU (1) | RU2523596C2 (es) |
SI (1) | SI2143792T1 (es) |
TW (1) | TWI468515B (es) |
UA (1) | UA101806C2 (es) |
WO (1) | WO2008140126A1 (es) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110055965A1 (en) * | 2008-02-15 | 2011-03-03 | Hiroshi Abe | Cycle single-stranded nucleic acid complex and method for producing the same |
SG185544A1 (en) * | 2010-05-14 | 2012-12-28 | Fluidigm Corp | Nucleic acid isolation methods |
DK2431466T3 (en) * | 2010-07-08 | 2016-01-11 | Bonac Corp | Single-stranded nucleic acid molecule for the control of gene expression |
US8785121B2 (en) | 2010-07-08 | 2014-07-22 | Bonac Corporation | Single-stranded nucleic acid molecule for controlling gene expression |
US8691782B2 (en) | 2010-08-03 | 2014-04-08 | Bonac Corporation | Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton |
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
WO2012045082A2 (en) | 2010-10-01 | 2012-04-05 | Jason Schrum | Engineered nucleic acids and methods of use thereof |
AR083445A1 (es) | 2010-10-14 | 2013-02-27 | Univ Mie | siARN CONTRA LA FIBROSIS |
US9115167B2 (en) | 2011-03-10 | 2015-08-25 | Biomics Biotechnologies Co., Ltd. | Multi-targets interfering RNA molecules and their applications |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP3682905B1 (en) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
WO2013077446A1 (ja) * | 2011-11-26 | 2013-05-30 | 株式会社ボナック | 遺伝子発現制御のための一本鎖核酸分子 |
DK2791160T3 (da) | 2011-12-16 | 2022-05-30 | Modernatx Inc | Modificerede mrna-sammensætninger |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
US9663784B2 (en) | 2012-05-26 | 2017-05-30 | Bonac Corporation | Single-stranded nucleic acid molecule for regulating expression of gene having delivering function |
HRP20220607T1 (hr) | 2012-11-26 | 2022-06-24 | Modernatx, Inc. | Terminalno modificirana rna |
JP6296434B2 (ja) * | 2013-01-25 | 2018-03-20 | 国立研究開発法人理化学研究所 | 機能性核酸分子の構築法 |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
WO2014186334A1 (en) | 2013-05-15 | 2014-11-20 | Robert Kruse | Intracellular translation of circular rna |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
CN104419704B (zh) * | 2013-09-05 | 2016-09-14 | 中国科学院上海生命科学研究院 | 一种内含子来源环形rna分子及其成环关键核酸序列的应用 |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
WO2015099122A1 (ja) | 2013-12-26 | 2015-07-02 | 学校法人東京医科大学 | 遺伝子発現制御のための人工ミミックmiRNAおよびその用途 |
CA2935022A1 (en) | 2013-12-27 | 2015-07-02 | Bonac Corporation | Artificial match-type mirna for controlling gene expression and use therefor |
EP3239297B1 (en) | 2014-12-27 | 2021-03-10 | Bonac Corporation | Naturally occuring mirna for controlling gene expression, and use of same |
US11142769B2 (en) | 2015-03-27 | 2021-10-12 | Bonac Corporation | Single-stranded nucleic acid molecule having delivery function and gene expression regulating ability |
CN105063210A (zh) * | 2015-08-12 | 2015-11-18 | 中国农业科学院北京畜牧兽医研究所 | 一种环状rna的鉴定方法 |
CN107557363B (zh) * | 2016-06-30 | 2021-03-12 | 中国科学院分子细胞科学卓越创新中心 | 可诱导型siRNA表达载体及其制备和应用 |
US20200038427A1 (en) | 2017-03-31 | 2020-02-06 | Bonac Corporation | Cyclic nucleic acid molecule having gene expression control function |
CA3061322A1 (en) | 2017-04-28 | 2019-10-23 | Kyowa Kirin Co., Ltd. | Oligonucleotide derivative or salt thereof |
WO2018237372A1 (en) | 2017-06-23 | 2018-12-27 | Cornell University | RNA MOLECULES, METHODS FOR PRODUCING CIRCULAR RNA, AND METHODS OF TREATMENT |
WO2019051563A1 (en) * | 2017-09-15 | 2019-03-21 | Commonwealth Scientific And Industrial Research Organisation | RNA MOLECULES |
JP7208911B2 (ja) * | 2017-10-11 | 2023-01-19 | 日東電工株式会社 | 核酸分子発現の調節 |
JP2021508490A (ja) | 2017-12-15 | 2021-03-11 | フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー | 環状ポリリボヌクレオチドを含む組成物及びその使用 |
CN108251424A (zh) * | 2017-12-19 | 2018-07-06 | 天利康(天津)科技有限公司 | 一种单链环状rna和dna及其制备方法和应用 |
RU2020130258A (ru) | 2018-03-30 | 2022-05-04 | Торэй Индастриз, Инк. | Способ получения шпилечной одноцепочечной молекулы рнк |
JP2021526792A (ja) | 2018-06-06 | 2021-10-11 | マサチューセッツ インスティテュート オブ テクノロジー | 真核細胞における翻訳のための環状rna |
KR20210135529A (ko) | 2019-03-01 | 2021-11-15 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 폴리리보뉴클레오티드 및 이의 미용적 용도 |
US20220088049A1 (en) | 2019-03-01 | 2022-03-24 | Flagship Pioneering Innovations Vi, Llc | Compositions, methods, and kits for delivery of polyribonucleotides |
KR20210135265A (ko) | 2019-03-04 | 2021-11-12 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 원형 폴리리보뉴클레오티드 및 그의 약제학적 조성물 |
US20230072532A1 (en) | 2019-03-25 | 2023-03-09 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising modified circular polyribonucleotides and uses thereof |
SG11202112922WA (en) | 2019-05-22 | 2021-12-30 | Massachusetts Inst Technology | Circular rna compositions and methods |
CN114007655A (zh) | 2019-06-14 | 2022-02-01 | 旗舰创业创新第六有限责任公司 | 用于细胞疗法的环状rna |
US20220305128A1 (en) | 2019-06-19 | 2022-09-29 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising circular polyribonucleotides for protein modulation and uses thereof |
WO2020257727A1 (en) | 2019-06-19 | 2020-12-24 | Flagship Pioneering Innovations Vi, Llc | Methods of dosing circular polyribonucleotides |
EP3920976B1 (en) | 2019-12-04 | 2023-07-19 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
TW202142239A (zh) | 2020-01-29 | 2021-11-16 | 美商旗艦先鋒創新有限責任公司 | 包含環狀多核糖核苷酸之組合物之遞送 |
EP4096682A1 (en) | 2020-01-29 | 2022-12-07 | Flagship Pioneering Innovations VI, LLC | Compositions for translation and methods of use thereof |
WO2021236952A1 (en) | 2020-05-20 | 2021-11-25 | Flagship Pioneering, Inc. | Compositions and methods for producing human polyclonal antibodies |
WO2021236980A1 (en) | 2020-05-20 | 2021-11-25 | Flagship Pioneering Innovations Vi, Llc | Coronavirus antigen compositions and their uses |
TW202208629A (zh) | 2020-05-20 | 2022-03-01 | 美商旗艦先鋒創新有限責任公司 | 免疫原性組成物及其用途 |
AU2021336976A1 (en) | 2020-09-03 | 2023-03-23 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and uses thereof |
AU2022234607A1 (en) | 2021-03-10 | 2022-10-27 | Rznomics Inc. | Self-circularized RNA structure |
CA3229816A1 (en) * | 2021-08-27 | 2023-03-02 | Wensheng Wei | Constructs and methods for preparing circular rna |
AU2022397292A1 (en) | 2021-11-24 | 2024-05-30 | Flagship Pioneering Innovations Vi, Llc | Varicella-zoster virus immunogen compositions and their uses |
AU2022398478A1 (en) | 2021-11-24 | 2024-06-13 | Flagship Pioneering Innovations Vi, Llc | Coronavirus immunogen compositions and their uses |
AU2022397300A1 (en) | 2021-11-24 | 2024-06-27 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and their uses |
CN118510896A (zh) | 2021-12-17 | 2024-08-16 | 旗舰创业创新六公司 | 用于在变性条件下富集环状rna的方法 |
TW202340461A (zh) | 2021-12-22 | 2023-10-16 | 美商旗艦先鋒創新有限責任公司 | 用於純化多核糖核苷酸之組成物和方法 |
TW202342064A (zh) | 2021-12-23 | 2023-11-01 | 美商旗艦先鋒創新有限責任公司 | 編碼抗融合多肽之環狀多核糖核苷酸 |
CN115786374B (zh) * | 2022-07-06 | 2023-10-13 | 广州吉赛生物科技股份有限公司 | 一种利用鱼腥藻内含子自剪切核酶精准制备环状rna的方法 |
WO2024097664A1 (en) | 2022-10-31 | 2024-05-10 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for purifying polyribonucleotides |
CN116694638A (zh) * | 2023-02-20 | 2023-09-05 | 天津微环生物医药科技有限责任公司 | 环状核酸应用-miRNA抑制剂 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11137260A (ja) | 1997-11-06 | 1999-05-25 | Soyaku Gijutsu Kenkyusho:Kk | 抗インフルエンザウイルス環状ダンベル型rna−dnaキメラ化合物及び抗インフルエンザウイルス剤 |
US6210931B1 (en) * | 1998-11-30 | 2001-04-03 | The United States Of America As Represented By The Secretary Of Agriculture | Ribozyme-mediated synthesis of circular RNA |
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
WO2000063364A2 (en) * | 1999-04-21 | 2000-10-26 | American Home Products Corporation | Methods and compositions for inhibiting the function of polynucleotide sequences |
WO2003070918A2 (en) * | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
WO2002044321A2 (en) * | 2000-12-01 | 2002-06-06 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Rna interference mediating small rna molecules |
WO2003070197A2 (en) * | 2002-02-20 | 2003-08-28 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF TGF-BETA AND TGF-BETA RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20040019001A1 (en) * | 2002-02-20 | 2004-01-29 | Mcswiggen James A. | RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA |
US20090247606A1 (en) * | 2001-08-28 | 2009-10-01 | Sirna Therapeutics, Inc. | RNA Interference Mediated Inhibition of Adenosine A1 Receptor (ADORA1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
GB2397062B (en) * | 2002-02-20 | 2005-06-15 | Sirna Therapeutics Inc | RNA interference mediated inhibition of hepatitis c virus (HCV) gene expression using short interfering nucleic acid (siNA) |
AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
US7501503B2 (en) * | 2002-12-31 | 2009-03-10 | Mcgill University | Compositions and methods for inhibiting RNase H activity of retroid reverse transcriptase |
WO2005001063A2 (en) * | 2003-06-25 | 2005-01-06 | Somagenics, Inc. | Polynucleotides capable of target-dependent circularization and topological linkage |
US7972816B2 (en) * | 2003-08-08 | 2011-07-05 | National Institute Of Advanced Industrial Science And Technology | Efficient process for producing dumbbell DNA |
US20060051789A1 (en) * | 2004-07-01 | 2006-03-09 | Somagenics, Inc. | Methods of preparation of gene-specific oligonucleotide libraries and uses thereof |
-
2007
- 2007-05-09 JP JP2007125045A patent/JP5296328B2/ja not_active Expired - Fee Related
-
2008
- 2008-05-07 AR ARP080101917A patent/AR072034A1/es unknown
- 2008-05-09 MY MYPI20094697A patent/MY154495A/en unknown
- 2008-05-09 EP EP08764303.7A patent/EP2143792B1/en active Active
- 2008-05-09 AU AU2008250075A patent/AU2008250075B2/en not_active Ceased
- 2008-05-09 PL PL08764303T patent/PL2143792T3/pl unknown
- 2008-05-09 US US12/598,974 patent/US20100137407A1/en not_active Abandoned
- 2008-05-09 NZ NZ581251A patent/NZ581251A/en not_active IP Right Cessation
- 2008-05-09 KR KR1020097025654A patent/KR101525633B1/ko not_active IP Right Cessation
- 2008-05-09 CN CN200880015108A patent/CN101679962A/zh active Pending
- 2008-05-09 WO PCT/JP2008/058990 patent/WO2008140126A1/ja active Application Filing
- 2008-05-09 UA UAA200912771A patent/UA101806C2/ru unknown
- 2008-05-09 ES ES08764303.7T patent/ES2446040T3/es active Active
- 2008-05-09 SI SI200831175T patent/SI2143792T1/sl unknown
- 2008-05-09 CA CA002685994A patent/CA2685994A1/en not_active Abandoned
- 2008-05-09 DK DK08764303.7T patent/DK2143792T3/da active
- 2008-05-09 PT PT87643037T patent/PT2143792E/pt unknown
- 2008-05-09 RU RU2009145502/10A patent/RU2523596C2/ru not_active IP Right Cessation
- 2008-05-09 MX MX2009011101A patent/MX2009011101A/es active IP Right Grant
- 2008-05-09 BR BRPI0811440-4A2A patent/BRPI0811440A2/pt not_active IP Right Cessation
- 2008-05-09 TW TW97117329A patent/TWI468515B/zh not_active IP Right Cessation
-
2009
- 2009-11-05 IL IL201975A patent/IL201975A/en not_active IP Right Cessation
- 2009-12-09 CO CO09140877A patent/CO6241167A2/es not_active Application Discontinuation
-
2010
- 2010-03-25 HK HK10103140.1A patent/HK1135140A1/xx not_active IP Right Cessation
-
2014
- 2014-02-25 HR HRP20140170AT patent/HRP20140170T1/hr unknown
- 2014-03-24 CY CY20141100228T patent/CY1115283T1/el unknown
-
2017
- 2017-08-21 US US15/681,884 patent/US20180073020A1/en not_active Abandoned
-
2018
- 2018-12-28 US US16/235,656 patent/US20190292538A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6241167A2 (es) | Arn circular monocatenario y metodo para producirlo | |
EA200800838A1 (ru) | Модуляция иммуностимулирующих свойств короткой интерферирующей рибонуклеиновой кислоты (siphk) с помощью модификации нуклеотидов | |
NZ631512A (en) | Compositions and methods for modulating apolipoprotein (a) expression | |
ES2674129T3 (es) | Agentes terapéuticos de base aptámeros útiles en el tratamiento de trastornos relacionados con complemento | |
RU2010120715A (ru) | Модифицированная липидом двухцепочечная рнк, обладающая сильным эффектом рнк-интерференции | |
AU2008339215A8 (en) | Novel siRNA structure for minimizing off-target effects and relaxing saturation of RNAi machinery and the use thereof | |
WO2008078180A3 (en) | Materials and methods for the generation of transcripts comprising modified nucleotides | |
WO2020198509A3 (en) | Modified oligonucleotides with increased stability | |
MX359400B (es) | Reduccion de metal pesado en plantas. | |
SG171676A1 (en) | Compositions and methods for inhibiting expression of the pcsk9 gene | |
SG170780A1 (en) | Compositions and methods for inhibiting expression of eg5 gene | |
WO2006018836A3 (en) | Nucleic acid constructs and cells, and methods utilizing same for modifying the electrophysiological function of excitable tissues | |
EP2322617A3 (en) | Short interfering ribonucleic acid (siRNA) for oral administration | |
ES2676600T3 (es) | Fabricación y uso de ARN monocatenario sintetizado in vitro para la introducción en células de mamífero para inducir un efecto biológico o bioquímico | |
WO2006110688A3 (en) | Rnai therapeutic for respiratory virus infection | |
AR086272A2 (es) | Anticuerpos anti-factor d humanizados y sus usos | |
ATE483032T1 (de) | Verfahren zur herstellung von oligonukleotiden | |
NZ603339A (en) | Modulation of transthyretin expression | |
MY153691A (en) | Hydroxymethyl substituted rna oligonucleotides and rna complexes | |
JP2010500029A5 (es) | ||
WO2012170957A3 (en) | Retinoid-liposomes for enhancing modulation of hsp47 expression | |
RU2013102545A (ru) | Связывающая vegfa си-рнк и способы лечения in vivo | |
MXPA05001355A (es) | Formas nuevas adicionales de moleculas de arn de interferencia. | |
WO2008036933A3 (en) | Compositions and methods for inhibiting expression of the hamp gene | |
MX350510B (es) | Aminación (r)-selectiva. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |